NDAORALTABLET
Approved
Feb 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
GIAZO (balsalazide disodium) by Bausch + Lomb is mesalamine, which is the therapeutically active portion of the molecule, and the 4-aminobenzoyl-β-alanine carrier moiety. Approved for ulcerative colitis, inflammatory bowel disease. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GIAZO (balsalazide disodium) is an oral small-molecule 5-aminosalicylic acid (5-ASA) prodrug approved for ulcerative colitis and inflammatory bowel disease. It works by delivering mesalamine directly to the colon, where it is believed to reduce inflammation by inhibiting arachidonic acid metabolite production locally on the mucosa.
Peak5.1 years to LOE
GIAZO is in peak lifecycle stage but faces significant competition from JAK inhibitors and biologics; commercial team size likely modest relative to blockbuster competitors.
Mechanism of Action
mesalamine, which is the therapeutically active portion of the molecule, and the 4-aminobenzoyl-β-alanine carrier moiety. The carrier moiety released when balsalazide disodium is cleaved is only minimally absorbed and is largely inert. The mechanism of action of 5-ASA is unknown, but appears to be…
Indications (2)
Worked on GIAZO at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.